Celtic Pharma Welcomes the Results of the Sale Process of Inspiration Biopharmaceuticals' Hemophilia Assets to Cangene Corporation (CC:CNJ)
2/7/2013 9:47:32 AM
More...
|
Celtic Pharma: Data from New Drug Trial Offers Prospect for Enhanced Quality of Life for Children With Late Stage Brain Tumors
6/27/2012 9:19:36 AM
More...
|
Celtic Pharma Announces Completion of Enrollment in Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
10/3/2011 11:46:36 AM
More...
|
Celtic Pharma Announces Presentation of Preclinical Data at the 69th Annual Meeting of the American Academy of Dermatology in New Orleans
2/7/2011 6:47:51 AM
More...
|
Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept(R) in Combination with Avastin(R) as a Treatment for Breast and Colon Cancers
10/21/2010 7:36:39 AM
More...
|
Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
4/30/2010 10:49:16 AM
More...
|
Celtic Pharma Announces Preclinical Findings that XERECEPT(R) Potentiates Significantly the Tumor Inhibition Activity of Avastin(R)
4/19/2010 8:15:08 AM
More...
|
Celtic Pharma And PolyTherics Announce Investment Into Novel Biopharmaceutical Programme
1/26/2010 12:44:13 PM
More...
|
Celtic Pharma Announces Strategic Partnership Between Ipsen and Inspiration Biopharmaceuticals; Ipsen to Provide up to $259 Million of Funding to Inspiration
1/21/2010 6:54:37 AM
More...
|
Celtic Pharma Announces Investment in Novacta Biosystems
7/6/2009 9:48:13 AM
More...
|
|